MUS81 UFMylation at K400 promotes cell survival in response to camptothecin-induced replication stress
Qunsong Tan, Xingzhi Xu
MUS81 UFMylation at K400 promotes cell survival in response to camptothecin-induced replication stress
Camptothecin (CPT) is a widely used chemotherapeutic drug that acts by trapping topoisomerase I (TOP1) on DNA during replication. UFMylation is a ubiquitin-like modification involved in various cellular processes, including DNA double-strand break repair. The role of UFMylation in regulating replication-induced DNA damage within cells, however, is unclear. Through in vivo screening, we ascertained that the structure-specific endonuclease MUS81 is UFMylated. MUS81 is responsible for the progression and restarting of replication forks in human cells. We show that CPT triggered the UFMylation of MUS81 at lysine 400, which in turn prevented its ubiquitination-mediated degradation. Additionally, re-expression of WT MUS81, but not UFMylation defective mutant MUS81(K400R), in MUS81-depleted cells rescued CPT-induced cytotoxicity. Thus, the study revealed a new role for UFMylation in CPT-induced DNA damage, in which MUS81 UFMylation at K400 promotes cancer cell survival by inhibiting MUS81 degradation in response to CPT treatment, thus providing an attractive therapeutic strategy combining UFMylation inhibitors with CPT.
UFMylation / MUS81 / CPT / Ubiquitination / Cancer therapy
[] |
Banerjee, S., Kumar, M., & Wiener, R. (2020). Decrypting UFMylation: How proteins are modified with UFM1 biomolecules 10, Artn 144210.3390/Biom10101442.
|
[] |
Boddy, M. N., Gaillard, P. H. L., McDonald, W. H., Shanahan, P., Yates, J. R., & Russell, P. (2001). Mus81-Eme1 are essential components of a Holliday junction resolvase cell 107, 537–548 https://doi.org/10.1016/S0092-8674(01)00536-0
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
|
[] |
Qin, B., Yu, J., Nowsheen, S., Zhao, F., Wang, L. W., & Lou, Z. K. (2020). STK38 promotes ATM activation by acting as a reader of histone H4 ufmylation Science advances 6, ARTN eaax821410.1126/sciadv.aax8214.
|
[] |
|
[] |
Reuvers, T. G. A., Kanaar, R., & Nonnekens, J. (2020). DNA damage-inducing Anticancer therapies: From Global to Precision damage cancers 12, Artn 209810.3390/Cancers12082098.
|
[] |
Sun, Y., Miller Jenkins, L. M., Su, Y. P., Nitiss, K. C., Nitiss, J. L., & Pommier, Y. (2020). A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. Science Advances, 6. https://doi.org/10.1126/sciadv.aba6290
|
[] |
Sun, Y., Baechler, S. A., Zhang, X., Kumar, S., Factor, V. M., Arakawa, Y., Chau, C. H., Okamoto, K., Parikh, A., Walker, B., Su, Y. P., Chen, J., Ting, T., Huang, S. N., Beck, E., Itkin, Z., McKnight, C., Xie, C., Roper, N., & Pommier, Y. (2023). Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex Nature communications 14, 3762 https://doi.org/10.1038/s41467-023-39374-9
|
[] |
|
[] |
|
[] |
|
[] |
Wang, Z. F., Gong, Y. M., Peng, B., Shi, R. F., Fan, D., Zhao, H. C., Zhu, M., Zhang, H. X., Lou, Z. K., Zhou, J. W., Zhu, W. G., Cong, Y. S., & Xu, X. Z. (2019). MRE11 UFMylation promotes ATM activation nucleic acids research 47, 4124–4135 https://doi.org/10.1093/nar/gkz110
|
[] |
Wyatt, H. D. M., Laister, R. C., Martin, S. R., Arrowsmith, C. H., & West, S. C. (2017). The SMX DNA repair tri-nuclease Mol Cell 65, 848– https://doi.org/10.1016/j.molcel.2017.01.031
|
/
〈 | 〉 |